What happened?
The EMA 'What’s new' list for 14/10/2026 records multiple updates and new entries for paediatric investigation plans (PIPs). The entries name specific PIPs (for example for mifepristone; misoprostol, linaprazan glurate, ivonescimab and tislelizumab) and indicate new or updated regulatory records relating to planned paediatric studies.
Why does it matter?
PIPs define the studies and timing required to evaluate medicines in children. Updates on the EMA page show regulators continuing to agree or amend paediatric development requirements as sponsors progress or revise clinical plans.
How to interpret the evidence
This is an index-style update: it signals regulatory activity on paediatric development but is not a final authorisation or study report. Details of required studies, ages, endpoints and timelines are in the underlying PIP assessments and should be checked for specific medicines. Applicability in the EU, including Malta, depends on whether the product is pursued under the EU centralised procedure or national routes.
What remains uncertain?
These listings are not marketing-authorisation approvals, paediatric labelling changes or trial results. They do not guarantee local availability, nor do they specify study outcomes, patient numbers or clinical recommendations.
Medical News provides general health education. Individual treatment decisions depend on your circumstances and the advice of your clinical team.
This summary was prepared with AI assistance and checked automatically against the linked primary source. It has not been individually reviewed by a clinician.